The safety and efficacy of AFM11 have been evaluated in two open-label, multicenter, dose-escalation phase 1 studies, in patients with r/r CD19-positive B-cell non-Hodgkin lymphoma (NHL) (AFM11-101) and in patients with CD19-positive B-precursor Philadelphia-chromosome-negative (Ph-) ALL (AFM11-102). Here, CD19 is linked to B-cell non-Hodgkin lymphoma.